Efocipegtrutide vs UBT251
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
Efocipegtrutide
Developed by Hanmi Pharmaceutical
NCT03374241 · Phase 1 · completed
The study was randomized, blinded and placebo-controlled, a solid safety-study design, but its only primary measure was a count of adverse events rather than a clinical or weight-related efficacy outcome, and no statistical test was applied to those counts. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants With Adverse Events (1 month): Number of Participants With Adverse Events (1 month): Cohort 1 Active 3 Participants | Cohort 2 Active 2 Participants | Cohort 3 Active 3 Participants | Cohort 4 Active 7 Participants | Cohort 5 Active 4 Participants | Placebo 7 Participants (not_applicable)
Result source: NCT03374241
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07785934 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Efocipegtrutide | UBT251 |
|---|---|---|
| Body weight, % change | —Not reported | —Trial running · NCT07806851 |
| Weight loss of 5% or more | —Not reported | —Trial running · NCT07806851 |
| Weight loss of 10% or more | —Not reported | —Trial running · NCT07806851 |
| Waist circumference, change (cm) | —Not reported | —Trial running · NCT07806851 |
Body weight, % change
- Efocipegtrutide
- —Not reported
- UBT251
- —Trial running · NCT07806851
Weight loss of 5% or more
- Efocipegtrutide
- —Not reported
- UBT251
- —Trial running · NCT07806851
Weight loss of 10% or more
- Efocipegtrutide
- —Not reported
- UBT251
- —Trial running · NCT07806851
Waist circumference, change (cm)
- Efocipegtrutide
- —Not reported
- UBT251
- —Trial running · NCT07806851
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UBT251: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Efocipegtrutide: 3 of 4 rows · UBT251: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Efocipegtrutide |
|---|---|
| Dropout rate | —Cohort 1 Activea NCT03374241 · Phase 1 show 9 more results—Cohort 2 Active NCT03374241 · Phase 1 —Cohort 3 Active NCT03374241 · Phase 1 —Cohort 4 Active NCT03374241 · Phase 1 —Cohort 5 Active NCT03374241 · Phase 1 11.1%0.08 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 16.7%0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —Cohort 1 Activea NCT03374241 · Phase 1 show 9 more results—Cohort 2 Active NCT03374241 · Phase 1 —Cohort 3 Active NCT03374241 · Phase 1 —Cohort 4 Active NCT03374241 · Phase 1 —Cohort 5 Active NCT03374241 · Phase 1 —0.08 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%Cohort 1 Activea NCT03374241 · Phase 1 show 9 more results0%Cohort 2 Active NCT03374241 · Phase 1 0%Cohort 3 Active NCT03374241 · Phase 1 0%Cohort 4 Active NCT03374241 · Phase 1 0%Cohort 5 Active NCT03374241 · Phase 1 0%0.08 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a general disorders and administration 33.3% (placebo 40%) infections and infestations 16.7% (placebo 0%) musculoskeletal and connective tissue 16.7% (placebo 0%) NCT03374241 · Phase 1 show 9 more resultsblood and lymphatic system disorders 16.7% (placebo 0%) general disorders and administration 16.7% (placebo 40%) nervous system disorders 16.7% (placebo 20%) NCT03374241 · Phase 1 musculoskeletal and connective tissue 33.3% (placebo 0%) eye disorders 16.7% (placebo 0%) general disorders and administration 16.7% (placebo 40%) NCT03374241 · Phase 1 gi disorders 57.1% (placebo 10%) nervous system disorders 57.1% (placebo 20%) general disorders and administration 28.6% (placebo 40%) NCT03374241 · Phase 1 gi disorders 66.7% (placebo 10%) infections and infestations 33.3% (placebo 0%) nervous system disorders 33.3% (placebo 20%) NCT03374241 · Phase 1 0.08 mg/kg nausea 33.3% (placebo 5.9%) bone contusion 11.1% (placebo 0%) decreased appetite 11.1% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.06 mg/kg nausea 33.3% (placebo 5.9%) decreased appetite 22.2% (placebo 5.9%) chest pain 11.1% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.04 mg/kg glucose urine present 16.7% (placebo 5.9%) nausea 16.7% (placebo 5.9%) upper respiratory tract infection 16.7% (placebo 17.6%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.02 mg/kg injection site erythema 20% (placebo 0%) animal bite 10% (placebo 0%) decreased appetite 10% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.01 mg/kg upper respiratory tract infection 44.4% (placebo 17.6%) injection site erythema 11.1% (placebo 0%) nausea 11.1% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Efocipegtrutide
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Efocipegtrutide's landscape · UBT251's landscape